Multinationals Boost Tianjin’s Green Transformation

Novo Nordisk, a Danish company specializing in obesity treatment, has been operating in Tianjin for over three decades.

As one of the company’s global strategic production bases, the Tianjin plant has established a circular, zero-pollution assessment model, set ambitious zero-carbon goals for each production chain, and achieved 100 percent reliance on green electricity and water recycling, all through the use of intelligent technologies.

In 1995, Novo Nordisk opened its first production site, a packaging facility, in Tianjin. In 2002, it were the first pharmaceutical company to open a biopharmaceutical R&D centre in China. In 2008, the company began construction of a new high-tech insulin filling plant in Tianjin. The year 2024 will mark the 30th anniversary of Novo Nordisk China. With the mission of “Driving Change, Working Together to Defeat Serious Chronic Diseases”, Novo Nordisk has continued to increase its investment and formed a whole industry chain layout covering the three major engines of research and development, production, and operation.